Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals, Inc.

Sector: Pharmaceutical Preparations Region: MA, United States

: | Nasdaq: IDRA | OTC Markets: IDRAW

Similar to: Shire PLC, Pernix Therapeutics Holdings, Inc., Cephalon, Inc.

Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which is engaged in the discovery and development of novel synthetic DNA- and RNA-based drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors. The company has two drug candidates, IMO-3100, a TLR7 and TLR9 antagonist, and IMO-8400, a TLR7, TLR8, and TLR9 antagonist, in clinical development for the treatment of autoimmune and inflammatory diseases. Idera Pharmaceuticals was founded by Paul C. Zamecnik, Sudhir A. Agrawal and James B. Wyngaarden in May 25, 1989 and is headquartered in Cambridge, MA.

News & Analysis

You may also be interested in: